Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 956Neoplasms 755Carcinoma, Non-Small-Cell Lung 742Prostatic Neoplasms 569Colorectal Neoplasms 499Lung Neoplasms 444Neoplasm Metastasis 400Multiple Myeloma 371Leukemia, Myeloid, Acute 351Ovarian Neoplasms 307Pancreatic Neoplasms 301Melanoma 273Squamous Cell Carcinoma of Head and Neck 257Recurrence 248Carcinoma, Hepatocellular 229Glioblastoma 223Brain Neoplasms 219Head and Neck Neoplasms 199Triple Negative Breast Neoplasms 198Carcinoma, Renal Cell 197Precursor Cell Lymphoblastic Leukemia-Lymphoma 190Lymphoma 188Stomach Neoplasms 186Endometrial Neoplasms 177Lymphoma, Non-Hodgkin 172Sarcoma 168Glioma 165Uterine Cervical Neoplasms 160Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 157

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Mucinous Adenocarcinoma × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡